Pacira BioSciences, Inc.
PCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $871,256 | $1,559,530 | $1,757,566 | $2,663,245 |
| - Cash | $276,774 | $153,298 | $104,139 | $585,578 |
| + Debt | $638,853 | $586,044 | $763,394 | $1,128,848 |
| Enterprise Value | $1,233,335 | $1,992,276 | $2,416,821 | $3,206,515 |
| Revenue | $700,966 | $674,978 | $666,823 | $541,533 |
| % Growth | 3.9% | 1.2% | 23.1% | – |
| Gross Profit | $530,538 | $490,309 | $467,528 | $401,278 |
| % Margin | 75.7% | 72.6% | 70.1% | 74.1% |
| EBITDA | $29,118 | $154,585 | $140,379 | $113,948 |
| % Margin | 4.2% | 22.9% | 21.1% | 21% |
| Net Income | -$99,560 | $41,955 | $15,909 | $41,980 |
| % Margin | -14.2% | 6.2% | 2.4% | 7.8% |
| EPS Diluted | -2.15 | 0.89 | 0.34 | 0.92 |
| % Growth | -341.6% | 161.8% | -63% | – |
| Operating Cash Flow | $189,389 | $154,649 | $145,274 | $125,717 |
| Capital Expenditures | -$10,636 | -$15,161 | -$30,076 | -$45,866 |
| Free Cash Flow | $178,753 | $139,488 | $115,198 | $79,851 |